Noema Pharma

Executive Summary

Noema Pharma is a Swiss clinical-stage biotechnology company founded in 2019 and based in Basel, dedicated to developing novel small-molecule therapies for underserved neurological and neuropsychiatric disorders. The company's pipeline targets conditions with high unmet medical need, aiming to provide superior clinical benefits across both orphan indications and broader neurology markets. Currently in Phase 1 development, Noema leverages deep expertise in CNS drug discovery to advance candidates that modulate key disease pathways, with a focus on precision medicine approaches. The company's strategy emphasizes rapid proof-of-concept studies and efficient clinical development, positioning it to deliver meaningful treatments for patients who currently have limited options. With a strong scientific foundation and a clear focus on high-impact indications, Noema represents a promising opportunity in the neurology space, though it remains early-stage with limited public data.

Upcoming Catalysts (preview)

• Q2 2026Phase 1 top-line data for lead candidate in chronic pain indication60% success
• Q4 2026Initiation of Phase 2 trial in Tourette syndrome or related tic disorder70% success
• Q3 2026Regulatory update on orphan drug designation for lead program80% success